Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.41 – $1.49
Volume10,537
Market cap$6M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.45M
Price / earnings
—
Price / book
0.8×
Price / sales
—
EV / sales
—
EV / EBITDA
0.22×
Profitability
Earnings per share
-$2.70
Return on assets
-135.16%
Return on equity
-149.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
10.21×
Quick ratio
10.21×
Cash ratio
9.63×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.56M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ENVB, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.64M
$1.25M
$1.78M
$1.43M
$1.22M
$1.36M
$2.12M
$1.2M
Research and development
$1.36M
$345.97K
$372.18K
$402.42K
$1.26M
$746.37K
$967.4K
$802.72K
Total operating expenses
$3.03M
$1.63M
$2.19M
$1.87M
$2.52M
$2.19M
$3.17M
$2.08M
Operating income
-$3.03M
-$1.63M
-$2.19M
-$1.87M
-$2.52M
-$2.19M
-$3.17M
-$2.08M
Interest expense
-$292
$0
-$250
$274
-$132
$0
-$225
-$217
Income before taxes
-$3.03M
-$1.63M
-$2.19M
-$1.87M
-$2.52M
-$2.18M
-$3.15M
-$2.08M
Income taxes
$0
$0
$0
$0
$0
$0
$7.2K
$0
Net income
-$3.03M
-$1.63M
-$2.19M
-$1.87M
-$2.52M
-$2.18M
-$3.15M
-$2.08M
Net income attributable to common shareholders
-$3.03M
-$1.63M
-$4.04M
-$3.39M
-$2.52M
-$2.18M
-$3.15M
-$2.08M
EBITDA
-$2.99M
-$1.6M
-$2.15M
-$1.83M
-$2.48M
-$2.11M
-$3.09M
-$2M
Basic earnings per share
-$0.76
-$1.08
-$6.13
-$10.81
-$11.65
-$14.58
-$57.46
-$43.10
Diluted earnings per share
-$0.76
-$1.08
-$6.13
-$10.81
-$11.65
-$14.58
-$57.46
-$43.10
Recent news
Company coverage with links to the original publishers.
Enveric Biosciences (NASDAQ: ENVB) surged over 106% in premarket trading following President Trump's executive order directing federal agencies to accelerate approval timelines for psychedelic-based treatments. The administration also committed $50 million to ibogaine research. While momentum is improving with positive MACD signals, the stock remains 47.2% below its 200-day moving average, indicating the rally occurs within a longer-term downtrend.
Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.